endometrial hyperplasia

(redirected from Hyperplasia without atypia)

endometrial hyperplasia

increase in the number of endometrial glands, usually secondary to hyperestrinism; classified as simple hyperplasia, complex hyperplasia, or complex hyperplasia with atypia; the latter may progress to adenocarcinoma.

endometrial hyperplasia

an abnormal condition characterized by overgrowth of the endometrium resulting from sustained stimulation by estrogen (of endogenous or exogenous origin) that is not opposed by progesterone. Estrogen acts as a growth hormone for the endometrium. Through a complex intercellular mechanism, endometrial cells bind estrogen preferentially and undergo changes characteristic of the proliferative phase of the menstrual cycle. If estrogen stimulation continues for 3 to 6 months without periodic cessation or counteractive progesterone stimulation, as occurs in anovulatory or perimenopausal women and in those receiving replacement estrogen without added progestogen, the endometrium becomes abnormally thickened and glandularized. Unremitting estrogen stimulation eventually causes cystic or adenomatous endometrial hyperplasia. The latter is a premalignant lesion that undergoes malignant degeneration in approximately 25% of cases. The causative relationship between estrogen and endometrial hyperplasia is well established; there is some indication but no proof that estrogen also provokes the change from hyperplasia to neoplasia and malignancy. Endometrial hyperplasia often results in abnormal uterine bleeding. Such bleeding, particularly in older women, constitutes an indication for biopsy or curettage of the endometrium to establish histopathological diagnosis and to rule out malignancy. A functioning estrogen-secreting tumor is suspected if the woman is not taking estrogen medication. Progestogen therapy is effective in reversing the abnormal histopathological changes of endometrial hyperplasia. If hyperplasia is adenomatous, hysterectomy is commonly performed.

endometrial hyperplasia

Adenomatous hyperplasia of endometrium Gynecology A premalignant endometrial lesion of older ♀
Endometrial hyperplasia
Hyperplasia without atypia Glands are crowded w/o cytologic atypia; these have a < 2% progress to carcinoma
Simple hyperplasia Glands are not back-to-back
Complex hyperplasia Glands are back-to-back
Hyperplasia with atypia Glands are crowded with cytologic atypia; ± 23% progress to carcinoma

en·do·me·tri·al hy·per·pla·si·a

(en'dō-mē'trē-ăl hī'pĕr-plā'zē-ă)
Increase in the number of endometrial glands, usually secondary to hyperestrinism; classified as simple hyperplasia, complex hyperplasia, or complex hyperplasia with atypia; the latter may progress to adenocarcinoma.
References in periodicals archive ?
In a study by Vaidya et al, simple hyperplasia without atypia was in 1.
9%) had endometrial hyperplasia without atypia, and 5(5%) had endometrial hyperplasia with atypia.
Hyperplasia without atypia progresses to carcinoma in 1.
There were 25 women with simple endometrial hyperplasia without atypia (the first study group), 15 patients with hyperplastic endometrial polyps (the second study group) and 40 healthy women with endometrium in the early proliferative phase (control group) in premenopausal age.
Treatment of endo- metrial hyperplasia without atypia in postmenopa- usal women with a levonorgestrel intrauterine device has been suggested to be an effective and safe alter- native.
Comment: Endometrial hyperplasia without atypia in premenopausal women is commonly treated with a progestin.
Conclusions: These results suggest that genistein aglycone might be useful for the management of endometrial hyperplasia without atypia in women that cannot be treated with progestin.
Indeed, a close evaluation of some illustrations (publications) as examples of columnar cell hyperplasia without atypia reveals flat epithelial atypia, if one pays more attention to the diagnostic criteria as introduced and emphasized by Azzopardi.
The authors analysed Rb2/p130 expression by immunohistochemistry staining in 102 specimens chosen to represent a spectrum of endometrial changes, including proliferative endometrium (n = 18), secretory endometrium (n = 18), simple or complex hyperplasia without atypia (n = 18), atypical hyperplasia (n = 18), and invasive carcinoma (n = 30).
Panel B shows proliferative hyperplasia without atypia.
28%) cases of complex hyperplasia without atypia showed complete loss of or diminished expression of phophotase and tensin homologue.